Compare AMRC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRC | ZYME |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2010 | 2017 |
| Metric | AMRC | ZYME |
|---|---|---|
| Price | $30.67 | $26.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $33.22 | $32.75 |
| AVG Volume (30 Days) | 468.7K | ★ 589.6K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.87 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $1,883,767,000.00 | $134,481,000.00 |
| Revenue This Year | $9.83 | $63.57 |
| Revenue Next Year | $9.83 | $89.45 |
| P/E Ratio | $24.61 | ★ N/A |
| Revenue Growth | 12.22 | ★ 116.21 |
| 52 Week Low | $8.49 | $9.03 |
| 52 Week High | $44.93 | $28.49 |
| Indicator | AMRC | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 57.49 |
| Support Level | $28.72 | $26.10 |
| Resistance Level | $30.90 | $26.91 |
| Average True Range (ATR) | 1.24 | 0.95 |
| MACD | 0.13 | -0.25 |
| Stochastic Oscillator | 58.50 | 49.84 |
Ameresco Inc provides energy efficiency solutions for facilities in North America and Europe. It focuses on projects that reduce energy, also focuses on the operations and maintenance costs of governmental, educational, utility, healthcare, and other institutional, commercial, and industrial entities facilities. Ameresco distributes solar energy products and systems, such as PV panels, solar regulators, solar charge controllers, inverters, solar-powered lighting systems, solar-powered water pumps, solar panel mounting hardware, and other system components. The company's segment includes U.S. Regions; U.S. Federal; Canada; Alternative Fuels; Non-Solar DG and All Other. It derives a majority of its revenue from the U.S. Regions segment.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.